Acceleron Pharma Inc. (XLRN) Has Broken Out To A New High On Study Results
Markets2018-06-29
20 Views
Acceleron Pharma Inc. (XLRN) and Celgene (CELG) announced after the bell Thursday that the Phase 3 study of Luspatercept met its primary and key secondary endpoints.
Source: RTTNews
The news, reports, views and opinions of authors (or source) expressed are their own and do not necessarily represent the views of CRWE World.
Moderna (Nasdaq: MRNA) Announces Amendment to Current Supply Agreement with United Kingdom Government for an Additional 2 Million Doses of mRNA Vaccine Against COVID-19 (mRNA-1273)
